Abstract: Disclosed are compounds represented by the formula:(I), wherein R is as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are a method of treating a subject in need of treatment for a bacterial infection or a fungal infection, which includes administering to the subject an effective amount of one of the compounds or salts thereof. Further disclosed is a process for producing the compounds and salts thereof.

Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.

Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.

Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from Chrysophaeum taylori. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.

Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from Chrysophaeum taylori. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.

Abstract: Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is 0 or 1; R1, R2 and R3 independently are H, aralkyl, acyl, lower alkyl or silyl; X is —C(O)N(R4)— or —C(S)N(R4)—; —C(O)—; —C(S)—; Y is —OC(O)—; —OC(O)N(R5)—; —N(R5)C(O)—; or —OC(O)O—; G comprises a saturated or unsaturated aliphatic chain having from 2 to about 10 atoms in the chain, the chain optionally including 1, 2, or 3 heteroatoms; the chain optionally being substituted with 1, 2 or 3 substituents independently selected from lower alkyl, —OR6, epoxy, aziridinyl, cyclopropyl, —NR7R8 and halo; R4, R5, R6, R7 and R8 independently are selected from H, lower alkyl and acyl. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions including one or more of the disclosed macrocycles.

Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.

Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.

Abstract: The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention compounds are naturally occurring compounds obtained from marine sponges and other organisms. The invention further provides methods for using the compounds to inhibit virulence and reduce antibiotic resistance of mycothiol-producing bacteria.

Abstract: The present invention relates to a purified or isolated obligate domain-swapped dimer of CVN and a composition comprising the same.

Abstract: This invention relates to a novel peptide inhibitor of a HIV fusion that disrupts the internal trimeric coiled-coil of gp41, to a pharmaceutical composition that comprise this inhibitor, and to methods of treating immunodeficiency disease, especially HIV, that employ such a pharmaceutical composition.

Abstract: This invention provides a trimeric protein complex that presents an exposed N-terminal coiled-coil domain from the HIV gp41 protein. The preferred embodiment of the invention inhibits membrane fusion mediated by HIV virus. The invention also provides methods to use the trimeric protein complexes as a vaccines to prevent infection by the HIV virus.

Abstract: A purified or isolated obligate domain-swapped dimer of CVN; an isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector; a host cell comprising such an isolated or purified nucleic acid; a composition comprising (i) the obligate domain-swapped dimer of CVN or the isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector, and (ii) a carrier therefor; a method of inhibiting a viral infection of a mammal, which method comprises administering to the mammal an antiviral effective amount of the aforementioned composition, whereupon the viral infection of the mammal is inhibited; and a method of making an obligate domain-swapped dimer of CVN, which method comprises introducing at least one mutation in the linker region of wild-type CVN, whereupon an obligate domain-swapped dimer of CVN is obtained.

Abstract: The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention compounds are naturally occurring compounds obtained from marine sponges and other organisms. The invention further provides methods for using the compounds to inhibit virulence and reduce antibiotic resistance of mycothiol-producing bacteria.